Our study shows that common pro-inflammatory and SASP-associated factors, TNFα and IL-6, were both significantly reduced by sirolimus treatment in both normal and early cancer, which confirms a role of mTOR signaling in promoting the secretion of SASP factors. The gene discussed is IL6; the disease is cancer.